1534 related articles for article (PubMed ID: 10770728)
1. Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America.
Rex JH; Walsh TJ; Sobel JD; Filler SG; Pappas PG; Dismukes WE; Edwards JE
Clin Infect Dis; 2000 Apr; 30(4):662-78. PubMed ID: 10770728
[TBL] [Abstract][Full Text] [Related]
2. Non-albicans Candida spp. causing fungaemia: pathogenicity and antifungal resistance.
Krcmery V; Barnes AJ
J Hosp Infect; 2002 Apr; 50(4):243-60. PubMed ID: 12014897
[TBL] [Abstract][Full Text] [Related]
3. Fungal infections in patients undergoing bone marrow transplantation: an approach to a rational management protocol.
Castagnola E; Bucci B; Montinaro E; Viscoli C
Bone Marrow Transplant; 1996 Nov; 18 Suppl 2():97-106. PubMed ID: 8932808
[TBL] [Abstract][Full Text] [Related]
4. Candidemia in a tertiary care cancer center: in vitro susceptibility and its association with outcome of initial antifungal therapy.
Antoniadou A; Torres HA; Lewis RE; Thornby J; Bodey GP; Tarrand JP; Han XY; Rolston KV; Safdar A; Raad II; Kontoyiannis DP
Medicine (Baltimore); 2003 Sep; 82(5):309-21. PubMed ID: 14530780
[TBL] [Abstract][Full Text] [Related]
5. Candida krusei fungaemia: antifungal susceptibility and clinical presentation of an uncommon entity during 15 years in a single general hospital.
Muñoz P; Sánchez-Somolinos M; Alcalá L; Rodríguez-Créixems M; Peláez T; Bouza E
J Antimicrob Chemother; 2005 Feb; 55(2):188-93. PubMed ID: 15650001
[TBL] [Abstract][Full Text] [Related]
6. Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America.
Saag MS; Graybill RJ; Larsen RA; Pappas PG; Perfect JR; Powderly WG; Sobel JD; Dismukes WE
Clin Infect Dis; 2000 Apr; 30(4):710-8. PubMed ID: 10770733
[TBL] [Abstract][Full Text] [Related]
7. Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry.
Horn DL; Neofytos D; Anaissie EJ; Fishman JA; Steinbach WJ; Olyaei AJ; Marr KA; Pfaller MA; Chang CH; Webster KM
Clin Infect Dis; 2009 Jun; 48(12):1695-703. PubMed ID: 19441981
[TBL] [Abstract][Full Text] [Related]
8. Fluconazole for the management of invasive candidiasis: where do we stand after 15 years?
Charlier C; Hart E; Lefort A; Ribaud P; Dromer F; Denning DW; Lortholary O
J Antimicrob Chemother; 2006 Mar; 57(3):384-410. PubMed ID: 16449304
[TBL] [Abstract][Full Text] [Related]
9. Update on clinical antifungal susceptibility testing for Candida species.
Lewis RE; Klepser ME; Pfaller MA
Pharmacotherapy; 1998; 18(3):509-15. PubMed ID: 9620102
[TBL] [Abstract][Full Text] [Related]
10. Management of mycoses in surgical patients -- review of the literature.
Holzheimer RG; Dralle H
Eur J Med Res; 2002 May; 7(5):200-26. PubMed ID: 12069912
[TBL] [Abstract][Full Text] [Related]
11. Candida endophthalmitis: focus on current and future antifungal treatment options.
Khan FA; Slain D; Khakoo RA
Pharmacotherapy; 2007 Dec; 27(12):1711-21. PubMed ID: 18041891
[TBL] [Abstract][Full Text] [Related]
12. [Therapy of invasive organ mycoses in patients with systemic hematologic diseases].
Karthaus M; Böhme A
Wien Med Wochenschr; 2001; 151(3-4):80-8. PubMed ID: 11789423
[TBL] [Abstract][Full Text] [Related]
13. Antifungal resistance in pathogenic fungi.
Perea S; Patterson TF
Clin Infect Dis; 2002 Nov; 35(9):1073-80. PubMed ID: 12384841
[TBL] [Abstract][Full Text] [Related]
14. Adequacy of empirical antifungal therapy and effect on outcome among patients with invasive Candida species infections.
Parkins MD; Sabuda DM; Elsayed S; Laupland KB
J Antimicrob Chemother; 2007 Sep; 60(3):613-8. PubMed ID: 17576697
[TBL] [Abstract][Full Text] [Related]
15. Oral Candida isolates in patients undergoing radiotherapy for head and neck cancer: prevalence, azole susceptibility profiles and response to antifungal treatment.
Belazi M; Velegraki A; Koussidou-Eremondi T; Andreadis D; Hini S; Arsenis G; Eliopoulou C; Destouni E; Antoniades D
Oral Microbiol Immunol; 2004 Dec; 19(6):347-51. PubMed ID: 15491459
[TBL] [Abstract][Full Text] [Related]
16. Antifungal resistance: the clinical front.
Perfect JR
Oncology (Williston Park); 2004 Dec; 18(14 Suppl 13):15-22. PubMed ID: 15682590
[TBL] [Abstract][Full Text] [Related]
17. Resistance to antifungal agents in the critical care setting: problems and perspectives.
Martins MD; Rex JH
New Horiz; 1996 Aug; 4(3):338-44. PubMed ID: 8856751
[TBL] [Abstract][Full Text] [Related]
18. Update on antifungal treatment of invasive Candida and Aspergillus infections.
Maschmeyer G; Ruhnke M
Mycoses; 2004 Aug; 47(7):263-76. PubMed ID: 15310328
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of Candida species in different hospital wards and their susceptibility to antifungal agents: results of a three year survey.
Fadda ME; Podda GS; Pisano MB; Deplano M; Cosentino S
J Prev Med Hyg; 2008 Jun; 49(2):69-74. PubMed ID: 18847180
[TBL] [Abstract][Full Text] [Related]
20. Practice guidelines for the management of patients with blastomycosis. Infectious Diseases Society of America.
Chapman SW; Bradsher RW; Campbell GD; Pappas PG; Kauffman CA
Clin Infect Dis; 2000 Apr; 30(4):679-83. PubMed ID: 10770729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
